Market Research Logo

Ebola Viral Infections - Pipeline Review, H2 2015

Ebola Viral Infections - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Ebola Viral Infections - Pipeline Review, H2 2015’, provides an overview of the Ebola Viral Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ebola Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ebola Viral Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ebola Viral Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Ebola Viral Infections Overview
Therapeutics Development
Pipeline Products for Ebola Viral Infections - Overview
Pipeline Products for Ebola Viral Infections - Comparative Analysis
Ebola Viral Infections - Therapeutics under Development by Companies
Ebola Viral Infections - Therapeutics under Investigation by Universities/Institutes
Ebola Viral Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Ebola Viral Infections - Products under Development by Companies
Ebola Viral Infections - Products under Investigation by Universities/Institutes
Ebola Viral Infections - Companies Involved in Therapeutics Development
Abivax S.A.
AmVac AG
AnGes MG, Inc.
Arno Therapeutics, Inc.
Canopus BioPharma Incorporated
Crucell N.V.
Emergent BioSolutions Inc.
Enyo Pharma S.A.S.
Epirus Biopharmaceuticals, Inc.
Etubics Corporation
FIT Biotech Oy
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Globavir Biosciences, Inc.
Hemispherx Biopharma, Inc.
Humabs BioMed SA
Immune Response BioPharma, Inc.
Immunovaccine, Inc.
Inovio Pharmaceuticals, Inc.
Kineta, Inc.
Kymab Limited
Medicago Inc.
Merck & Co., Inc.
Microbiotix, Inc.
Micropharm Limited
Navigen Pharmaceuticals, Inc.
Novavax, Inc.
Peregrine Pharmaceuticals, Inc.
Phelix Therapeutics, LLC
RedHill Biopharma Ltd.
Regeneron Pharmaceuticals, Inc.
SignPath Pharma Inc
Sihuan Pharmaceutical Holdings Group Ltd.
SKAU Vaccines ApS
Tamir Biotechnology, Inc.
Toyama Chemical Co., Ltd.
United Therapeutics Corporation
Vaxeal Holding SA
XBiotech USA, Inc.
Ebola Viral Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ABX-544 - Drug Profile
Ad5-EBOV vaccine - Drug Profile
AMV-701 - Drug Profile
ANSX-109 - Drug Profile
ANSX-142 - Drug Profile
Antibody for Ebola Viral Infection - Drug Profile
AR-12 - Drug Profile
bavituximab - Drug Profile
CB-007 - Drug Profile
CB-008 - Drug Profile
DEF-201 - Drug Profile
DLANA-14 - Drug Profile
DPX-Ebola - Drug Profile
Drug for Ebola Virus Infection - Drug Profile
Drugs to Inhibit Cathepsin B for Ebola Viral Infections - Drug Profile
Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile
ebola + rabies vaccine - Drug Profile
ebola [strain sudan, zaire] + marburg vaccine - Drug Profile
ebola [strain zaire] (monovalent) vaccine - Drug Profile
ebola [strain zaire] vaccine - Drug Profile
ebola [zaire] vaccine - Drug Profile
ebola [zaire] vaccine - Drug Profile
ebola vaccine - Drug Profile
ebola vaccine - Drug Profile
ebola vaccine - Drug Profile
ebola vaccine - Drug Profile
ebola vaccine - Drug Profile
ebola vaccine - Drug Profile
ebola vaccine - Drug Profile
ebola vaccine - Drug Profile
ebola vaccine - Drug Profile
ebola vaccine 1 - Drug Profile
ebola vaccine 2 - Drug Profile
ebola virus like particle vaccine - Drug Profile
ebola virus like particle vaccine - Drug Profile
Ebola virus vaccine - Drug Profile
EBOTAb - Drug Profile
ET-007 - Drug Profile
favipiravir - Drug Profile
FBH-004 - Drug Profile
FDX-000 - Drug Profile
GBV-006 - Drug Profile
Gene Therapy for Ebola Virus Infections - Drug Profile
GreEMTri - Drug Profile
GS-5734 - Drug Profile
imatinib mesylate - Drug Profile
INO-4212 - Drug Profile
interferon alfa-n3 - Drug Profile
IRE-101 - Drug Profile
JK-05 - Drug Profile
KV-7005 - Drug Profile
Lipocurc - Drug Profile
MIL-77 - Drug Profile
MMCatLMC - Drug Profile
Monoclonal Antibodies for Ebola Viral Infections - Drug Profile
Monoclonal Antibodies for Ebola Virus Infection - Drug Profile
Monoclonal Antibodies for Viral Infections - Drug Profile
MonoClonal Antibody for Ebola and Marburg Infections - Drug Profile
Monoclonal Antibody for Ebola Viral Infections - Drug Profile
Monoclonal Antibody for Ebola Virus Infections - Drug Profile
NCK-8 - Drug Profile
NoBola - Drug Profile
OS-2966 - Drug Profile
rintatolimod - Drug Profile
Small Molecule to Agonize IRF-3 for Viral Infections - Drug Profile
Small Molecule to Inhibit Cathepsin L for SARS and Ebola Viral Infections - Drug Profile
Small Molecules for Ebola Viral Infections - Drug Profile
Small Molecules for Ebola Virus Infection - Drug Profile
Small Molecules for Ebola Virus Infections - Drug Profile
Small Molecules to Inhibit Cathepsin L for Ebola Virus Infection - Drug Profile
Small Molecules to Inhibit Niemann Pick C1 for Ebola Viral Infections - Drug Profile
Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile
Small Molecules to Inhibit Nucleoprotein for Ebola Virus Infections - Drug Profile
Small Molecules to Target Estrogen Receptor for Ebola Virus Infection - Drug Profile
Synthetic Peptides for Ebola Virus - Drug Profile
thiocarbazate - Drug Profile
TMR-004 - Drug Profile
UV-4B - Drug Profile
V-920 - Drug Profile
ZMAb - Drug Profile
ZMapp - Drug Profile
Ebola Viral Infections - Recent Pipeline Updates
Ebola Viral Infections - Dormant Projects
Ebola Viral Infections - Discontinued Products
Ebola Viral Infections - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Ebola Viral Infections, H2 2015
Number of Products under Development for Ebola Viral Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2015
Ebola Viral Infections - Pipeline by Abivax S.A., H2 2015
Ebola Viral Infections - Pipeline by AmVac AG, H2 2015
Ebola Viral Infections - Pipeline by AnGes MG, Inc., H2 2015
Ebola Viral Infections - Pipeline by Arno Therapeutics, Inc., H2 2015
Ebola Viral Infections - Pipeline by Canopus BioPharma Incorporated, H2 2015
Ebola Viral Infections - Pipeline by Crucell N.V., H2 2015
Ebola Viral Infections - Pipeline by Emergent BioSolutions Inc., H2 2015
Ebola Viral Infections - Pipeline by Enyo Pharma S.A.S., H2 2015
Ebola Viral Infections - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Ebola Viral Infections - Pipeline by Etubics Corporation, H2 2015
Ebola Viral Infections - Pipeline by FIT Biotech Oy, H2 2015
Ebola Viral Infections - Pipeline by Gilead Sciences, Inc., H2 2015
Ebola Viral Infections - Pipeline by GlaxoSmithKline Plc, H2 2015
Ebola Viral Infections - Pipeline by Globavir Biosciences, Inc., H2 2015
Ebola Viral Infections - Pipeline by Hemispherx Biopharma, Inc., H2 2015
Ebola Viral Infections - Pipeline by Humabs BioMed SA, H2 2015
Ebola Viral Infections - Pipeline by Immune Response BioPharma, Inc., H2 2015
Ebola Viral Infections - Pipeline by Immunovaccine, Inc., H2 2015
Ebola Viral Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015
Ebola Viral Infections - Pipeline by Kineta, Inc., H2 2015
Ebola Viral Infections - Pipeline by Kymab Limited, H2 2015
Ebola Viral Infections - Pipeline by Medicago Inc., H2 2015
Ebola Viral Infections - Pipeline by Merck & Co., Inc., H2 2015
Ebola Viral Infections - Pipeline by Microbiotix, Inc., H2 2015
Ebola Viral Infections - Pipeline by Micropharm Limited, H2 2015
Ebola Viral Infections - Pipeline by Navigen Pharmaceuticals, Inc., H2 2015
Ebola Viral Infections - Pipeline by Novavax, Inc., H2 2015
Ebola Viral Infections - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015
Ebola Viral Infections - Pipeline by Phelix Therapeutics, LLC, H2 2015
Ebola Viral Infections - Pipeline by RedHill Biopharma Ltd., H2 2015
Ebola Viral Infections - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
Ebola Viral Infections - Pipeline by SignPath Pharma Inc, H2 2015
Ebola Viral Infections - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2015
Ebola Viral Infections - Pipeline by SKAU Vaccines ApS, H2 2015
Ebola Viral Infections - Pipeline by Tamir Biotechnology, Inc., H2 2015
Ebola Viral Infections - Pipeline by Toyama Chemical Co., Ltd., H2 2015
Ebola Viral Infections - Pipeline by United Therapeutics Corporation, H2 2015
Ebola Viral Infections - Pipeline by Vaxeal Holding SA, H2 2015
Ebola Viral Infections - Pipeline by XBiotech USA, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Ebola Viral Infections Therapeutics - Recent Pipeline Updates, H2 2015
Ebola Viral Infections - Dormant Projects, H2 2015
Ebola Viral Infections - Dormant Projects (Contd..1), H2 2015
Ebola Viral Infections - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Ebola Viral Infections, H2 2015
Number of Products under Development for Ebola Viral Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report